| |
|
FOUNDER
Sharon L. Monsky, 1953-2002
BOARD OF DIRECTORS
Luke Evnin, PhD, Chairman
Kristen Baker Bellamy
Nancy H. Bechtle
Dana Delany
Susan Desmond-Hellmann, MD, MPH
Susan Feniger
Bob Saget
Deann Wright
Caryn Zucker
SCIENTIFIC ADVISORY
BOARD
Bruce Alberts, PhD
National Academy of Sciences
David Botstein, PhD
Princeton University
Shaun R. Coughlin, MD, PhD
UC San Francisco
Regis B. Kelly, PhD
UC San Francisco
Henry Metzger, MD
National Institutes of Health
Antony Rosen, MD
Johns Hopkins University
William J. Rutter, PhD
Synergenics, LLC
Bruce U. Wintroub, MD
UC San Francisco
George Yancopoulos, MD, PhD
Regeneron Pharmaceuticals
|
|
|
|
| |
| |
| |
| |
|
|
 |
|
 |
 |
| SRF News & Events: |
San Francisco Cool Comedy - Hot Cuisine raises more than $500,000 for scleroderma research
The April 29 event honored business leader, philanthropist and scleroderma advocate, Nancy H. Bechtle at San Francisco's Palace Hotel. Actor/Comedian and SRF Board Member Bob Saget hosted the event, along with comedians Bill Bellamy and Dana Carvey and special musical guest Dave Koz. Attendees and donors brought in more than $500,000 toward improved therapies for people living with scleroderma. Proceeds will benefit the Scleroderma Center of Excellence at Johns Hopkins University - one of the most respected scleroderma clinics in the world. The SRF gratefully acknowledges our presenting sponsor, Actelion Pharmaceuticals, for their ongoing commitment and air partner Delta AirElite Business Jets for their participation. The next Cool Comedy - Hot Cuisine fundraiser is tentatively scheduled for early November in New York.
________________________________________________________________________________________
2008 Annual Report
The Scleroderma Research Foundation's 2008 Annual Report is now available for download. The Report outlines all research funding for the 2008-2009 fiscal year and includes donor and tribute lists. Also included are a description of the SRF research program, patient and volunteer profiles and a "year in review" letter by SRF Chairman Luke Evnin, PhD.
In addition to descriptions of all funded research, the 2008 Annual Report includes a "What this means for patients" paragraph about each project that explains how the research can benefit people living with scleroderma.
Please click here to view a PDF version of the Annual Report.
Please be patient. This is a very large file (19 MB) and may take several minutes to load depending on your connection speed. |
|
_________________________________________________________________________________________________________________
|
|
|
Actress and Scleroderma Research Foundation Board Member Dana Delany speaks out about her "hero" on CNN's "Sharing the Spotlight: Celebrity Heroes." Her hero, SRF Chairman Luke Evnin, PhD, is a scleroderma patient and general partner at one of the world's largest investors in life sciences.
Delany calls his efforts and accomplishments on behalf of the thousands of scleroderma patients "nothing less than heroic."
In her own words, "If anybody's going to solve this problem, it's going to be Luke."
The staff and Board of Directors of the SRF congratulate both Dana Delany and Luke Evnin on their success. We thank them for helping to raise the profile of this life-threatening illness and for their dedication to improved therapies and a cure.
Please visit the CNN link here to view the print and video versions of this story. |
|
|
| Research Funding Levels
The Scleroderma Research Foundation (SRF) has become the nation’s largest nonprofit investor in scleroderma research, raising more than $26,000,000—with every dollar coming from charitable gifts from generous individuals, corporations and foundations. In 2009, the SRF has provided more than $1,101,000 in direct research grants. Unlike university and medical foundations restricted to one institution, the SRF actively searches out the most promising researchers and laboratories aimed at helping scleroderma patients around the world. We are now funding research at Boston University, Dartmouth, Johns Hopkins, Harvard, Northwestern University, Stanford, the University of Michigan, University of Washington and the Royal Free Centre for Rheumatology in London, England. To make a contribution, please click here. |
 |
|
|
| |
There is currently no cure for scleroderma but,
in many cases, it can be managed.
|
About us:
The Scleroderma Research Foundation is a 501(c)(3) nonprofit organization whose mission is to find a cure for scleroderma by funding and facilitating the most promising, highest quality research and by placing the disease and the need for a cure in the public eye. Information provided by the SRF should not be considered medical advice, nor is it intended to replace consultation with a qualified physician. The SRF does not evaluate, endorse or recommend any particular medications, products, equipment or treatments. Scleroderma varies substantially from one patient to another, and treatment must be tailored by a physician for each individual case. |
|
|
